1. Macrophage and Tumor Cell Cross-Talk Is Fundamental for Lung Tumor Progression: We Need to Talk
   Poonam Sarode et al, 2020, Front. Oncol. CrossRef
2. Fractalkine/CX3CL1 in Neoplastic Processes
   Jan Korbecki et al, 2020, IJMS CrossRef
3. Development and Validation of a Seven-Gene Signature for Predicting the Prognosis of Lung Adenocarcinoma
   Yingqing Zhang et al, 2020, BioMed Research International CrossRef
4. Targeting NK Cells to Enhance Melanoma Response to Immunotherapies
   Hansol Lee et al, 2021, Cancers CrossRef
5. KIAA0101 as a new diagnostic and prognostic marker, and its correlation with gene regulatory networks and immune infiltrates in lung adenocarcinoma
   Sheng Hu et al, 2021, Aging CrossRef
6. Identification of VWF as a Novel Biomarker in Lung Adenocarcinoma by Comprehensive Analysis
   Yi He et al, 2021, Front. Oncol. CrossRef
7. A Novel Immune-Related Seventeen-Gene Signature for Predicting Early Stage Lung Squamous Cell Carcinoma Prognosis
   Tao Fan et al, 2021, Front. Immunol. CrossRef
8. Natural Killer Cells and Dendritic Cells: Expanding Clinical Relevance in the Non-Small Cell Lung Cancer (NSCLC) Tumor Microenvironment
   Pankaj Ahluwalia et al, 2021, Cancers CrossRef
9. Tertiary Lymphoid Structures and Chemokine Landscape in Virus-Positive and Virus-Negative Merkel Cell Carcinoma
   Motoki Nakamura et al, 2022, Front. Oncol. CrossRef
10. Structure and Function of Ligand CX3CL1 and its Receptor CX3CR1 in Cancer
    Xinjie Lu, 2022, CMC CrossRef
11. A systematic pan-cancer analysis reveals the clinical prognosis and immunotherapy value of C-X3-C motif ligand 1 (CX3CL1)
    Yidi Sun, 2023, Front. Genet. CrossRef
12. The role of molecular subtypes and immune infiltration characteristics based on disulfidptosis-associated genes in lung adenocarcinoma
    Cui Qi et al, 2023, Aging CrossRef
13. Neoadjuvant radiotherapy in ER+, HER2+, and triple-negative -specific breast cancer based humanized tumor mice enhances anti-PD-L1 treatment efficacy
    Christina Bruss et al, 2024, Front. Immunol. CrossRef
14. KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma
    Jan Budczies et al, 2024, Br J Cancer CrossRef
15. null
    Luis Exequiel Ibarra et al, 2024 CrossRef